## Infliximab (Remicade) Order Form

## **DEMOGRAPHICS**

PatientName:		DateofBirth:			Gender: □F□M				
			Cell:Work:						
					State:	Zip:			
Logally Dagnanai bla Danzagantatiyay				RelationshiptoPatient:					
Diagno ICD-10: CHFHis TBHisto	story?	□ Crohn's Disease □ Plaquepsoriasis □ No Date oflastPPD:	□Alkylosi	atoidArthritis ngSpondylitis 'Class Result:	□ <b>O</b> :	cerativeColitis ther:	□Psoriaticarthr	itis	
□ Alteplase2mglVtodeclot centrallVaccessperInfusionSolutionsprotocolasneededforocclusion. □ Flush with 0.9% NaCl and/orHeparin 10 u/ml or 100 u/ml per Infusion Solutions protocol. □ Lidocaine 1% - up to 0.2ml intradermally PRN (may buffer with sodium bicarbonate 8.4% in 10:1ratio).  Infliximab: Administration Frequency: □Onedose □3 doses (at 0, 2, and6weeks) □Maintenanceeveryweeks □ 3 doses (at 0, 2, and 6 weeks) followed byinfusionsevery weeksthereafterDose: RPh will round UP to nearest multipleof100 □Give exact									
□ 5mg/kg over at least 2hour □ 3mg/kg over at least2						se based on actual b	d on actual body weight		
		□ Other: mg/kg	over at leas	t 2hours**			usion Rate Chart		
To Man	Infuse o according If change mmHg) slow or may res cation (15 Diphenh Acetamin Other: nage Infus Methylp Infusion	250mg 0.9% NaCl to a fin fuse other medications the ver at least 2 hours. Beging to Infusion Rate Chart. In vital signs (ie: diastolion adverse reaction (ie: unstop infusion immediately. The properties of the p	al concentr rough the sa at 10ml/hr blood pres ticaria, shortr After sympto nl/hr.  25mgIV 500mgF  ePRNsevere er Infusion S (1,000mg if g IV x1 dose	ation of 0.4 to 4 meline and increase ra asure drops 15-2 ness of breath)or oms have resolve  PO  eurticaria,pruritis SolutionsProtoco severe) PO Q4 PRN urticaria,	ccurs, ed,  orSOB(Not): h PRN acpruritis, ors	Infusion Ra 10 ml/hr 20 ml/hr 40 ml/hr 150 ml/hr 250 ml/hr 250 ml/hr	For 15 min For 30 min Until end o	(min) nutes nutes nutes nutes nutes	
Nursing Orders:    If no central IV access, RN to insert peripheral IV, rotate site every 72 to 120 hours or asneeded.   Weight should be taken before eachdose.   Monitorvitalsigns(pulse &bloodpressure)beforetherapyandevery15to30minuntil30minaftertherapy.   If an infusion reaction occurs, decrease rate and monitor vital signs until symptoms subside. If reaction persists or worsens, stop infusion and notifyphysician.   Observe patient for 30 minutes after completion oftherapy.   Other:									
Labs:		□CBCwithDiff □ Hepaticfunctionpanel □ CRP □ Other:		□ateachdose □ateachdose □ateachdose	□every □every □every □every				
PrescriberSignature Date									

Please Print Name NPI